Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HRS9531 in obese patients with heart failure with preserved ejection fraction
CTR20241326Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- May 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in heart failure with preserved ejection fraction (HFpEF), obesity, sponsored by Fujian Shengdi Pharmaceuticals. Started May 2024; status: active.
02
Drugs
HRS9531
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on CTR20241326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241326.